首页>投融资
Terns Pharmaceuticals
增发
Terns Pharmaceuticals, Inc.于2016年12月9日根据开曼群岛法律注册成立。于2020年12月29日,该公司根据开曼群岛公司法(2020年修订)进行撤销注册及根据特拉华州普通公司法第388条进行归化(方式为向特拉华州州务卿提交归化证书),据此,其注册成立司法管辖权由开曼群岛变更为特拉华州,TernsPharmaceuticals Inc.是一家临床阶段的生物制药公司,开发用于治疗非酒精性脂肪性肝炎(NASH)和其他慢性肝病的小分子单剂和联合治疗候选药物组合。
基本信息
-
公司全称Terns Pharmaceuticals Inc
-
类型分子靶向、口服小分子创新药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数51~100人
-
地址1065 East Hillsdale Blvd. Suite 100 Foster City California 94404
-
联系电话1-650-5255535
-
邮箱info@ternspharma.com
-
成立时间2016-01-01
投融资
-
2024-09-12增发1.73亿美元未透露
-
2022-12-23增发8630万美元未透露
-
2021-02-05上市1.19亿美元未透露
-
2021-01-05C轮8700万美元Samsara CapitalSuvretta Capital Management维梧资本奥博资本礼来亚洲基金Deerfield
-
2018-10-30B轮8000万美元奥博资本礼来亚洲基金维梧资本德诚资本
-
2018-04-04A轮3000万美元礼来亚洲基金
- 加载更多
相关投融资企业
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
未公开
Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses.In January 2022, Leyden Laboratories B.V. closed a $140M Series B financing that raised a total of $200M in 2021.In March 2021, Leyden Labs had closed €40 Million Series A financing led by GV (Google Ventures), with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers
种子轮
RyboDyn是一家生物技术公司,率先开发针对暗基因组的一流免疫疗法。通过利用专有测序方法和先进的生物信息学平台 RyboCypher,RyboDyn™ 正在发现和验证以前未知的蛋白质和疾病特异性靶标。凭借其用于潜在客户发现和优化的可扩展内部平台以及从 Oregon Hea 获得许可的专有 IPlth & Science University,RyboDyn正在推动一种独特的“目标到资产”治疗方法进行开发。公司与领先的临床和学术机构以及生物制药合作伙伴合作,验证和推进其药物管线,专注于为癌症和其他医疗需求未得到满足的疾病提供变革性解决方案。